





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 401/04, 405/04, 409/04	A1	(11) International Publication Number: WO 91/07398 (43) International Publication Date: 30 May 1991 (30.05.91)
<p>(21) International Application Number: PCT/DK90/00304</p> <p>(22) International Filing Date: 22 November 1990 (22.11.90)</p> <p>(30) Priority data: 5882/89 22 November 1989 (22.11.89) DK</p> <p>(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).</p> <p>(72) Inventors: JAKOBSEN, Palle ; Langkær Vænge 14, DK-3500 Værløse (DK). SONNEWALD, Ursula ; Sildropveien 34B, N-7048 Trondheim (NO). TREPPENDAHL, Svend ; Frederiksdalsvej 221, DK-2830 Virum (DK).</p> <p>(74) Agent: LEHMANN & REE; Frederiksberg Allé 26, DK-1820 Frederiksberg C (DK).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: 4-HETEROARYL PIPERIDINE INTERMEDIATES AND THEIR PREPARATION</p>		
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div> </div>		
<p>(57) Abstract</p> <p>This invention relates to new compounds of formulae (I, II) in which X is O, S, or NR where R is H or C₁₋₄-alkyl, Z is hydrogen, halogen, trifluoromethyl, C₁₋₈-alkoxy, C₁₋₃-alkyl straight or branched, nitro, C₂₋₈-alkenyl, or a C₁₋₄-alkyl mono- or disubstituted amino group, R¹ is H or straight or branched C₁₋₈-alkyl. The invention also relates to a method of preparing a compound of formulae (I and II).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

4-HETEROARYL PIPERIDINE INTERMEDIATES AND THEIR PREPARATION

5

This invention relates to a novel chemical process for preparing new heteroaryl piperidine carbinols and to novel intermediates used in that process.


10

The novel compounds are useful as intermediates in processes leading to pharmacological active substances.

15

This invention relates to new compounds of formula I

20



I

25

in which X is O, S, or NR where R is H or C₁₋₄-alkyl, Z is hydrogen, halogen, trifluoromethyl, C₁₋₈-alkoxy, C₁₋₈-alkyl straight or branched, nitro, C₂₋₈-alkenyl, or a C₁₋₄-alkyl mono- or disubstituted amino group, R¹ is H or straight or branched C₁₋₈-alkyl.


30

The invention also relates to a method of preparing a compound of formula I.

35

This method which uses easily accessible commercially available starting materials comprises:

a) preparation of a compound of formula II




wherein X, Z, R and R¹ have the meaning defined above and R² is C₁₋₂-alkyl,

by reacting a compound of formula IV



with a compound of the formula V




25 under basic conditions eg. using alkoxide in ethanol, wherein X, Z, R, R¹ and R² have the meaning defined above and R³ being C₁₋₂-alkoxy when R⁴ is NHR¹ or R³ being NHR¹ when R⁴ is C₁₋₂-alkoxy,

30 b) reduction of a compound of formula II wherein X, Z, R, R¹ and R² have the meaning defined above, with metal hydride eg. LiAlH₄ or AlH₃ in ether or THF giving a compound of formula I wherein X, Z, R and R¹ have the meaning defined above,

35

c) reduction of a compound of formula III



10

wherein X, Z, R, R¹ and R² have the meaning defined above with a metal hydride eg. LiAlH₄ or AlH₃ giving a compound of formula I wherein X, Z, R and R¹ have the meaning defined above;

15


compounds of formula III can be prepared conveniently from Arecoline-type derivatives and metal organic derivatives of heteroaromatics using well known procedures,

20

d) compounds of formula I may also be prepared by reacting compounds of formula I wherein Z is H, with reagents causing heteroaromatic substitution using well known procedures,

25


e) compounds of formula I may be prepared by metal hydride reduction of a compound of formula VI



wherein X, Z, R, R¹ and R² have the meaning defined above,

f) compounds of formula II may be prepared in a one pot reaction using a compound of formula VII wherein X, Z and R have the meaning defined above


5



VII

as starting material. The reaction is carried out using ethyl acetate as solvent and methoxide or ethoxide as base. After initial reaction between VII and solvent a compound of formula VIII wherein R^1 and R^2 have the meaning defined above,

15



VIII

is added resulting in the formation of compounds of formula II wherein X, Z, R, R^1 and R^2 have the meaning defined above.

20

The invention will now be described in further detail with reference to the following examples.

EXAMPLE 1

25

3-hydroxymethyl-1-methyl-4-(2-thienyl)-piperidine (1)

30

3-methoxycarbonyl-1-methyl-4-(2-thienyl)-piperidine (2) was prepared from Arecoline, HBr (52 g), 2-bromothiophene (41 ml) and Mg-turnings (9.9 g) as described by Plati et. al. (J. Org. Chem. 22 (1957) 261). The resulting product was purified by distillation giving 15 g cis/trans mixture b.p. 50-120°C / 1.1 mm Hg.

35

30 g of this product was reduced with $LiAlH_4$ (5 g) in dry ether (200 ml) by reflux for 30 min. in N_2 -atmosphere. The well known rinse up procedure gave a hard

oil (21 g) identified as 3-hydroxymethyl-1-methyl-4-(2-thienyl)-piperidine(1) by ^1H NMR (CDCl_3), : 6.7 - 7.3 (3H,m); 3.8- 4.5 (1H,broad) 3.5-3.7 (2H,m); 2.8-3.5 (3H,m); 2.2 (3H,s); 1.8-2.8 (5H,m)

5

EXAMPLE 2

3-(2-thienyl)-propenoyl chloride (3) was prepared by dropwise addition of thionyl chloride (50 ml) to 3-
10 (2-thienyl)-propenoic acid (25 g) and subsequent heating to 60°C for 2 hours. Excess of SOCl_2 was evaporated in vacuo, CH_2Cl_2 was added and the reaction mixture was evaporated to dryness yielding 28 g of (3).

15 N-pentyl-3-(2-thienyl)-propenoic amide (4) was prepared from (3) (28 g) dissolved in dry toluene (200 ml) pentyl amine (25 ml) and triethyl amine (70 ml) was added under cooling (ice bath). Stirring for 1 hour. The precipitate of triethylammonium chloride was removed by
20 filtration, the filtrate was evaporated to dryness and the resulting mass treated with ether giving (4) as colourless crystals (22.8 g). ^1H NMR (CDCl_3), : 0.7-1.1 (3H,m); 1.1-1.7(6H,m); 3.0-3.4 (2H, dist.q), 6.2-8.2 (6H,m).

25

3-ethoxycarbonyl-1-pentyl-4-(2-thienyl)-piperidine 2,6-dione (5)

Sodium (3 g) was dissolved in abs. ethanol (60 ml), diethyl malonate (20 ml) dissolved in abs. ethanol (30
30 ml) was added followed by a slurry of (4) (22.8 g) in abs. ethanol (50 ml). Reflux for 4 hours, the ethanol was evaporated, toluene added (100 ml), and the reflux continued overnight. After cooling the formed precipitate was isolated, dissolved in 1M HCl and extracted
35 several times with ether. The combined ether phases were evaporated giving an oil which was purified on silica gel using $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 9/1 as eluent. Yield

22.6 g of (5) as an oil identified by ^1H NMR (CDCl_3), : 0.7-0.95 (3H,m); 1.0-1.5 (9H,m); 2.9-3.2 (2H,m) 4.15 (2H,q); 3.6-4.15 (4H,m); 6.8-7.2 (3H,m).

- 5 3-hydroxymethyl-1-pentyl-4-(2-thienyl)-piperidine (6)
was prepared from (5) (22.6 g) by reduction with LiAlH_4 (13 g) in dry THF. Reflux for 3 hours under N_2 . Using the well known work up procedure gave a hard oil (4 g) identified by ^1H NMR (CDCl_3), : 0.7-1.1 (3H,m); 1.1-1.7 (6H,m); 1.7-2.1 (4H,m); 2.1-3.9 (9H,m); 6.8-7.2 (3H,m).
10

EXAMPLE 3

- 15 N-pentyl-3-(3-thienyl)-propenoic amide (7) was prepared as described for (4). ^1H NMR (CDCl_3), : 0.7-1.1 (3H,m); 1.1-1.7 (6H,m); 3.2-3.6 (2H, dist. q); 6.1-7.8 (6H,m).

- 20 3-ethoxycarbonyl-1-pentyl-4-(3-thienyl)-piperidine-2,6-dione (8) was prepared as described for (5). 32 g (7) gave 41 g of crude (8) which was used without further purification. Reduction and work up as described for the preparation of (6) gave 7.7 g of crystalline 3-hydroxymethyl-1-pentyl-4-(3-thienyl)-piperidine (9).
25 M.p. 96.5-97.5°C.

EXAMPLE 4

- 30 (+)-1-butyl-3-ethoxycarbonyl-4-(2-thienyl)-2,6-piperidinedione (10)

- A solution of 2-thiophenecarbaldehyde (22.4 g) in ethyl acetate (20 ml) was added to a slurry of sodium ethoxide (32.6 g) in ethyl acetate (200 ml). The temperature was kept at 10°C and the mixture stirred for one hour. A solution of ethyl N-butylamidomalonate (41.2 g) in
35

ethyl acetate (40 ml) was slowly added to the mixture whilst keeping the temperature below 5°C. The mixture was stirred for 18 hours at 20°C and neutralized with 25% acetic acid (130 ml). The water phase was discharged and the organic phase extracted twice with saturated sodium chloride solution (2x50 ml). The organic phase was evaporated, the residue dissolved in toluene (200 ml), dried with potassium carbonate and evaporated to give the crude product. Yield 72 g of an oil identified by ¹H NMR (CDCl₃), : 0.7-1.4 (10H,m); 2.7-4.2 (8H,m); 6.7-7.3 (3H,m).

(+)-1-butyl-3-hydroxymethyl-4-(2-thienyl)-piperidine (11)

A solution of crude (+)-1-butyl-3-ethoxycarbonyl-4-(2-thienyl)-2,6-piperidindione (72 g) in toluene (100 ml) was added to a slurry of LiAlH₄ (15.2 g) in THF (100 ml) and toluene (50 ml). The temperature was kept below 10°C during the addition. The reaction mixture was stirred for 18 hours and decomposed by careful addition of water (75 ml) keeping the temperature below 10°C. The hydrolyzed mixture was stirred for 1 hour before the precipitated salts was filtered off. The filtrate was evaporated to give an oil (33 g) which was recrystallized from ethyl acetate (50 ml), filtered off and dried to give the title compound (17 g), m.p. 89.7-90.1°C.

30

EXAMPLE 5

(+)-1-butyl-3-ethoxycarbonyl-4-(5-methyl-2-furanyl)-2,6-piperidinedione (12)

was prepared from 5-methyl-2-furancarbaldehyde (22 g) as described for compound (10). Yield 59.5 g of an oil (80% pure by HPLC). Identified by ¹H NMR (CDCl₃) : 0.7-1.6 (10H, m), 2.2 - 2.4 (3H, d); 2.8 - 4.5 (8H, m);

5.8-7.5 (2H, m).

(+)-1-butyl-3-hydroxymethyl-4-(5-methyl-2-furanyl)-piperidine (13) was prepared from crude (12) (59 g) by reduction with LiAlH_4 , as described for (11). Yield 22 g of (13). M.p. 83.5°C .

EXAMPLE 6

(+)-1-butyl-3-ethoxycarbonyl-4-(1-methyl-2-pyrrolyl)-2,6-piperidinedione (14)

was prepared from 1-methyl-2-pyrrolicarbaldehyde (10.2 g) and ethyl *N*-butylamidomalonate (15.4 g) in ethyl acetate as described for compound (10). The crude product (27 g) was subsequently reduced without further purification as described for compound (11). Yield 14 g of

(+)-1-butyl-3-hydroxymethyl-4-(1-methyl-2-pyrrolyl)-piperidine (15) precipitated as the oxalate. ^1H NMR (CDCl_3) : 0.7-1.1 (3H, m); 1.1 - 2.2 (6H, m); 2.5 - 3.8 (10H, m), 3.5 (3H, s), 5.7 - 6.0 (2 H, m); 6.1 - 6.7 (1H, m).

EXAMPLE 7

3-Ethoxycarbonyl-1-(2-methylbutyl)-4-(3-thienyl)-2,6-piperidinedione (16)

was prepared from 3-thiophenecarbaldehyde (20 g) and ethyl *N*-(2-methylbutylamidomalonate) (35 g) in ethyl acetate as described for compound (10). The crude product (60 g oil) was reduced in THF by means of LiAlH_4 as described for compound (11) giving

3-hydroxymethyl-1-(2-methylbutyl)-4-(3-thienyl)-

piperidine (17)

The crude product (23 g) was purified on silica gel using ethyl acetate as eluent.

5

Mass spectrum (M^+ : 267) degradation in accordance with proposed structure. m.p. 88.8-90.2°C.

EXAMPLE 8

10

The following compounds were prepared exactly as described for (17) using the appropriate substituted thiophenecarbaldehyde and ethyl amidomalonate. The dione intermediate was used without purification.

15

3-hydroxymethyl-1-pentyl-4-(2-thienyl)piperidine (18)

Yield 17.6%; m.p. 107.6°C.

20

1-butyl-3-hydroxymethyl-4-(2-thienyl)piperidine (19)

Yield 27.2%; m.p. 90.9°C.

1-butyl-3-hydroxymethyl-4-(3-thienyl)piperidine (20)

25

Yield 27.9%; m.p. 81.7°C.

3-hydroxymethyl-1-pentyl-4-(3-thienyl)piperidine (21)


30

Yield 27.5%; m.p. 93.9°C.

35

CLAIMS

- 1) A process for the preparation of a compound of formula I




wherein X is O, S or NR, R is H or C₁₋₄-alkyl, Z is
 15 hydrogen, halogen, trifluoromethyl, C₁₋₈-alkoxy,
 straight or branched C₁₋₈-alkyl, nitro, C₂₋₈-alkenyl,
 or a C₁₋₄-alkyl mono- or disubstituted amino group,

R¹ is H, straight or branched C₁₋₈-alkyl;


20

the process comprises a preparation and reduction of a
 compound of formula II with a metal hydride eg. LiAlH₄



wherein X, Z, R and R¹ is defined above and R² is
 C₁₋₂-alkyl and the preparation and reduction of a
 compound of formula III by means of metal hydride
 35 eg. LiAlH₄


11



III

wherein X, Z, R, R¹ and R² have the meaning defined above


2) a compound of formula II



II


wherein X, Z, R, R¹, and R² have the meaning defined above

3) a process for the preparation of a compound of formula II



II

wherein X, Z, R, R¹ and R² have the meaning defined above, which comprises reacting a compound of formula IV



IV

with a compound of formula V




V

under basic conditions, wherein


X, Z, R, R¹ and R² have the meaning defined above, R³ being C₁₋₂-alkoxy when R⁴ is NHR¹ or R³ being NHR¹ when R⁴ is C₁₋₂-alkoxy.

4) a process for the preparation of a compound of formula II




II

wherein X, Z, R, R¹ and R² have the meaning defined above, which comprises reacting of a compound of formula VII



VII

wherein X, Z and R have the meaning defined above, with a compound of formula VIII



VIII

wherein R¹ and R² have the meaning defined above, in ethyl acetate using ethoxide or methoxide as base.

5) a compound which is 3-ethoxycarbonyl-1-pentyl-4-(2-thienyl)-piperidine-2,6-dione.

- 6) a compound which is 3-hydroxymethyl-1-methyl-4-(2-thienyl)-piperidine.
- 7) a compound which is 3-hydroxymethyl-1-pentyl-4-(3-thienyl)-piperidine.
- 8) a compound which is 3-ethoxycarbonyl-1-pentyl-4-(3-thienyl)-piperidine-2,6-dione.
- 9) a compound which is 3-methoxycarbonyl-1-methyl-4-(2-thienyl)-piperidine.
- 10) a compound which is 3-hydroxymethyl-1-pentyl-4-(2-thienyl)piperidine
- 11) a compound which is 1-butyl-3-hydroxymethyl-4-(2-thienyl)piperidine
- 12) a compound which is 1-butyl-3-hydroxymethyl-4-(5-methyl-2-furanyl)piperidine
- 13) a compound which is 1-butyl-3-hydroxymethyl-4-(3-thienyl)piperidine
- 14) a compound which is 3-hydroxymethyl-1-(2-methyl-butyl)-4-(3-thienyl)piperidine
- 15) a compound which is 1-butyl-3-hydroxymethyl-4-(1-methyl-2-pyrrolyl)piperidine.

30

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/DK 90/00304

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC5: C 07 D 401/04, 405/04, 409/04														
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 5px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 25%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px; height: 40px; vertical-align: bottom;">IPC5</td> <td style="padding: 5px; height: 40px; vertical-align: bottom;">C 07 D</td> </tr> </table> <div style="text-align: center; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched⁸</div> <p style="margin-top: 10px;">SE,DK;FI,NO classes as above</p>			Classification System	Classification Symbols	IPC5	C 07 D								
Classification System	Classification Symbols													
IPC5	C 07 D													
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <th style="width: 10%; padding: 5px;">Category *</th> <th style="width: 60%; padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 30%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A1, 0223334 (BEECHAM GROUP PLC) 27 May 1987, see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-15</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X A</td> <td style="padding: 5px;">EP, A2, 0190496 (BEECHAM GROUP PLC) 13 August 1986, see pages 1-19 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,3 2,5-15</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">US, A, 4007196 (JORGEN ANDERS CHRISTENSEN ET AL.) 8 February 1977, see the whole document -- -----</td> <td style="text-align: center; vertical-align: top; padding: 5px;">6-7,9-15</td> </tr> </table> <div style="margin-top: 10px;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>[*] Special categories of cited documents: ¹⁰</p> <p>^{"A"} document defining the general state of the art which is not considered to be of particular relevance</p> <p>^{"E"} earlier document but published on or after the international filing date</p> <p>^{"L"} document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>^{"O"} document referring to an oral disclosure, use, exhibition or other means</p> <p>^{"P"} document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>^{"T"} later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>^{"X"} document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>^{"Y"} document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>^{"&"} document member of the same patent family</p> </div> </div> </div>			Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A1, 0223334 (BEECHAM GROUP PLC) 27 May 1987, see the whole document --	1-15	X A	EP, A2, 0190496 (BEECHAM GROUP PLC) 13 August 1986, see pages 1-19 --	1,3 2,5-15	A	US, A, 4007196 (JORGEN ANDERS CHRISTENSEN ET AL.) 8 February 1977, see the whole document -- -----	6-7,9-15
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³												
X	EP, A1, 0223334 (BEECHAM GROUP PLC) 27 May 1987, see the whole document --	1-15												
X A	EP, A2, 0190496 (BEECHAM GROUP PLC) 13 August 1986, see pages 1-19 --	1,3 2,5-15												
A	US, A, 4007196 (JORGEN ANDERS CHRISTENSEN ET AL.) 8 February 1977, see the whole document -- -----	6-7,9-15												
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search 27th February 1991 </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report 1991-03-06 </td> </tr> <tr> <td style="width: 50%; padding: 5px; height: 40px; vertical-align: bottom;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div> </td> <td style="width: 50%; padding: 5px; height: 40px; vertical-align: bottom;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Göran Karlsson </div> </td> </tr> </table>			Date of the Actual Completion of the International Search 27th February 1991	Date of Mailing of this International Search Report 1991-03-06	International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Göran Karlsson </div>								
Date of the Actual Completion of the International Search 27th February 1991	Date of Mailing of this International Search Report 1991-03-06													
International Searching Authority <div style="text-align: center; margin-top: 10px;">SWEDISH PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;"> Göran Karlsson </div>													

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers ...2... and 5-15... because they relate to subject matter not required to be searched by this Authority, namely:

See annexed sheet !

2. ☐ Claim numbers, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(e).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE FIRST SHEET

Claims 2 and 5-15 can not be fully searched and categorized because the structure and the use of the pharmacological active substances are not specified in the description. According to Article 5, the description shall disclose the invention in a manner sufficiently clear and complete for the invention to be carried out by a person skilled in the art.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/DK 90/00304**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on **91-01-31**. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0223334	87-05-27	AU-B- 582456	89-03-23
		AU-D- 6101286	87-02-12
		JP-A- 62039566	87-02-20
		US-A- 4902801	90-02-20

EP-A2- 0190496	86-08-13	AU-D- 5111485	86-06-19
		JP-A- 61180769	86-08-13

US-A- 4007196	77-02-08	AT-B- 333759	76-12-10
		BE-A- 810310	74-05-16
		CA-A- 1038390	78-09-12
		CH-A- 592059	77-10-14
		DE-A-C- 2404113	74-08-08
		FR-A-B- 2215233	74-08-23
		GB-A- 1422263	76-01-21
		JP-C- 1268487	85-06-10
		JP-C- 1272362	85-07-11
		JP-A- 49101385	74-09-25
		JP-A- 58174363	83-10-13
		JP-B- 59046216	84-11-10
		JP-B- 59048826	84-11-29
		LU-A- 69264	74-04-10
		NL-A- 7401189	74-08-01
		SE-B-C- 401827	78-05-29
		US-A- 3912743	75-10-14
		BE-A- 893095	82-08-30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.